Nanoparticle mimics of heparan sulfate proteoglycans offer a new strategy for the inhibition of a range of viral infections.
References
Howard, C. R. & Fletcher, N. F. Emerg. Microbes Infect. 1, e46 (2012).
Plotkin, S. A. Nat. Med. 11, S5–S11 (2005).
Cagno, V. et al. Nat. Mater. 17, 195–203 (2018).
Wisskirchen, K., Lucifora, J., Michler, T. & Protzer, U. Trends Pharmacol. Sci. 35, 470–478 (2014).
Barnhart, M. Glob. Health Sci. Pract. 5, 182–187 (2017).
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S. & Bartenschlager, R. Nat. Rev. Drug Discov. 17, 35–56 (2018).
Gnanadhas, D. P. et al. J. Clin. Invest. 127, 857–873 (2017).
Xu, L. et al. Science 358, 85–90 (2017).
White, M. K., Hu, W. & Khalili, K. PLoS Pathog. 12, e1005953 (2016).
Vigant, F., Santos, N. C. & Lee, B. Nat. Rev. Microbiol. 13, 426–437 (2015).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Edagwa, B., Gendelman, H. Broad-spectrum antivirals. Nat. Mater. 17, 114–116 (2018). https://doi.org/10.1038/nmat5064
Published:
Issue Date:
DOI: https://doi.org/10.1038/nmat5064
- Springer Nature Limited
This article is cited by
-
Humanized Mice for Infectious and Neurodegenerative disorders
Retrovirology (2021)